[go: up one dir, main page]

MX2020003055A - Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. - Google Patents

Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.

Info

Publication number
MX2020003055A
MX2020003055A MX2020003055A MX2020003055A MX2020003055A MX 2020003055 A MX2020003055 A MX 2020003055A MX 2020003055 A MX2020003055 A MX 2020003055A MX 2020003055 A MX2020003055 A MX 2020003055A MX 2020003055 A MX2020003055 A MX 2020003055A
Authority
MX
Mexico
Prior art keywords
sub
compounds
polycyclic
pharmaceutical use
carbamoylpyridone compounds
Prior art date
Application number
MX2020003055A
Other languages
English (en)
Inventor
Michael R Mish
Xiaowu Chen
Elizabeth M Bacon
Jeromy J Cottell
Manoj C Desai
Scott E Lazerwith
James G Taylor
Zhenhong R Cai
Haolun Jin
Anthony Philip MORGANELLI
Mingzhe Ji
TREJO Teresa Alejandra MARTIN
Hyung-Jung Pyun
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2020003055A publication Critical patent/MX2020003055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga compuestos para el uso en el tratamiento de la infección de virus de la inmunodeficiencia humana (HIV). Los compuestos tienen la siguiente Fórmula (I): (ver Fórmula) que incluyen estereoisómeros y sus sales farmacéuticamente aceptables, donde R1, W, Y1, Y2, Z1 Y Z4 son como se definen en esta solicitud. Se divulgan además métodos asociados con la preparación y el uso de dichos compuestos, al igual que composiciones farmacéuticas que comprenden dichos compuestos.
MX2020003055A 2012-12-21 2015-06-18 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. MX2020003055A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745375P 2012-12-21 2012-12-21
US201361788397P 2013-03-15 2013-03-15
US201361845803P 2013-07-12 2013-07-12

Publications (1)

Publication Number Publication Date
MX2020003055A true MX2020003055A (es) 2020-07-27

Family

ID=49917297

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2017000362A MX357940B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2018009058A MX372534B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2015008009A MX344879B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2022013596A MX2022013596A (es) 2012-12-21 2015-06-18 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2020003055A MX2020003055A (es) 2012-12-21 2015-06-18 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
MX2017000362A MX357940B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2018009058A MX372534B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2015008009A MX344879B (es) 2012-12-21 2013-12-19 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2022013596A MX2022013596A (es) 2012-12-21 2015-06-18 Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.

Country Status (41)

Country Link
US (6) US9216996B2 (es)
EP (4) EP4122935A1 (es)
JP (6) JP6028105B2 (es)
KR (8) KR102527797B1 (es)
CN (4) CN107674086B (es)
AP (1) AP2015008510A0 (es)
AR (1) AR094197A1 (es)
AU (6) AU2013361401C1 (es)
BR (2) BR122015029881B1 (es)
CA (3) CA3131094A1 (es)
CL (3) CL2015001756A1 (es)
CR (2) CR20170279A (es)
CY (3) CY1117570T1 (es)
DK (3) DK3608325T3 (es)
EA (2) EA030003B1 (es)
ES (3) ES2753548T3 (es)
HR (3) HRP20220899T1 (es)
HU (4) HUE028284T2 (es)
IL (4) IL239316A (es)
LT (3) LT3608325T (es)
LU (1) LUC00083I2 (es)
MD (3) MD4754C1 (es)
ME (1) ME02400B (es)
MX (5) MX357940B (es)
MY (2) MY164352A (es)
NL (1) NL300947I2 (es)
NO (1) NO2018026I1 (es)
NZ (2) NZ709260A (es)
PE (2) PE20170528A1 (es)
PH (3) PH12019501848A1 (es)
PL (3) PL2822954T3 (es)
PT (3) PT3608325T (es)
RS (1) RS54873B1 (es)
SG (1) SG11201504857SA (es)
SI (3) SI3608325T1 (es)
SM (1) SMT201600157B (es)
TW (5) TWI815245B (es)
UA (2) UA114351C2 (es)
UY (1) UY35213A (es)
WO (1) WO2014100323A1 (es)
ZA (2) ZA201507997B (es)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
PT2841437T (pt) 2012-04-26 2017-09-28 Univ Montreal Derivados de imidazotiadiazol e imidazopirazina como inibidores de recetor 4 ativado por protease (par4) para o tratamento de agregação plaquetária
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
HUE028284T2 (en) 2012-12-21 2016-12-28 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
NO2865735T3 (es) * 2013-07-12 2018-07-21
PL3252058T3 (pl) 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
BR112016029612B1 (pt) 2014-06-17 2021-01-19 Pfizer Inc. compostos de di-hidroisoquinolinona substituídos
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) * 2014-06-20 2018-06-23
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) * 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
PL3236972T3 (pl) 2014-12-26 2022-03-07 Emory University Przeciwwirusowe pochodne n4-hydroksycytydyny
LT3097102T (lt) 2015-03-04 2018-01-25 Gilead Sciences, Inc. 4,6-diamino-pirido[3,2-d]pirimidino junginiai, moduliuojantys į toll panašius receptorius
EP3466490B1 (en) * 2015-04-02 2020-10-21 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP4424314A3 (en) * 2015-04-28 2025-02-19 Shionogi & Co., Ltd Substituted polycyclic pyridone derivative and prodrug thereof
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059120A1 (en) 2015-09-30 2017-04-06 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017083304A1 (en) * 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
BR112018012164A2 (pt) 2015-12-15 2018-12-04 Gilead Sciences Inc anticorpos neutralizantes do vírus da imunodeficiência humana
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3474857B1 (en) * 2016-06-23 2025-05-21 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
WO2018005328A1 (en) * 2016-06-27 2018-01-04 Concert Pharmaceuticals, Inc. Deuterated bictegravir
DK3347352T3 (da) 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
US10800772B2 (en) 2016-09-28 2020-10-13 Gilead Sciences, Inc. Therapeutic compounds
WO2018081292A1 (en) 2016-10-27 2018-05-03 Gilead Sciences, Inc. Crystalline forms of darunavir free base, hydrate, solvates and salts
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN108250215B (zh) * 2016-12-28 2022-04-19 华创合成制药股份有限公司 一种新型抗hiv药物及其制备方法和用途
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用
CN106860414B (zh) * 2017-02-16 2019-12-24 江苏艾迪药业股份有限公司 一种用于抗hiv的复方制剂及其制备方法与应用
ZA201803942B (en) 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
EP3642229A1 (en) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
RU2755710C2 (ru) 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
WO2019030625A1 (en) * 2017-08-09 2019-02-14 Viiv Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
WO2019030626A1 (en) * 2017-08-09 2019-02-14 Viiv Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
KR102714478B1 (ko) 2017-10-06 2024-10-10 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체의 입체 선택적인 제조 방법
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20190151307A1 (en) 2017-10-24 2019-05-23 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US11253524B2 (en) 2018-01-19 2022-02-22 Gilead Sciences, Inc. Metabolites of bictegravir
SI3749673T1 (sl) 2018-02-09 2022-07-29 Sandoz Ag Kristalinična oblika biktegravir natrija
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ， インコーポレイテッド Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
US11466031B2 (en) 2018-04-26 2022-10-11 Mylan Laboratories Limited Polymorphic forms of bictegravir and its sodium salt
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CN110526930B (zh) * 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
EP3805220B1 (en) 2018-05-31 2024-07-31 Shionogi & Co., Ltd Polycyclic carbamoylpyridone derivatives for the treatment of hiv
CR20200645A (es) 2018-05-31 2021-02-05 Shionogi & Co Derivado policiclíco de piridona
EP3815689A4 (en) 2018-06-27 2022-04-20 National University Corporation Hokkaido University ARENAVIRUS GROWTH INHIBITOR COMPRISING A POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
CN118063599A (zh) 2018-07-03 2024-05-24 吉利德科学公司 靶向hiv gp120的抗体和使用方法
ES2975333T3 (es) * 2018-07-12 2024-07-04 Laurus Labs Ltd Un proceso para la purificación de derivados policíclicos de carbamoilpiridona protegidos
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
JP7313438B2 (ja) 2018-09-19 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの予防のためのインテグラーゼ阻害剤
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020086555A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3653629A1 (en) 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
EP3886863A4 (en) 2018-11-29 2023-01-04 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
US12195480B2 (en) 2019-02-07 2025-01-14 Cipla Limited Polymorphs of integrase inhibitor
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
KR102707808B1 (ko) 2019-03-07 2024-09-19 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
US11084832B2 (en) * 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN110229174A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 Bictegravir原料药基因毒性杂质的合成方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN110263404B (zh) * 2019-06-12 2023-03-21 江苏大学 一种基于dpm模型的一体化预制泵站沉积特性的计算方法
WO2020255004A1 (en) * 2019-06-18 2020-12-24 Laurus Labs Limited Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
WO2021108544A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
US20230058677A1 (en) * 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
KR20230027275A (ko) 2020-06-25 2023-02-27 길리애드 사이언시즈, 인코포레이티드 Hiv 치료용 캡시드 저해제
EP4192474A1 (en) 2020-08-07 2023-06-14 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
AU2021351491C1 (en) * 2020-09-30 2025-06-12 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
WO2022089562A1 (zh) * 2020-10-30 2022-05-05 上海拓界生物医药科技有限公司 抑制基因缺陷的hiv病毒的用途
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
HUE064467T2 (hu) 2021-01-19 2024-03-28 Gilead Sciences Inc Szubsztituált piridotriazin-származékok és alkalmazásuk
EP4281076A4 (en) * 2021-01-22 2024-07-31 Laurus Labs Limited Processes for purification of bictegravir intermediates
CN114835730A (zh) * 2021-02-02 2022-08-02 齐鲁制药有限公司 一种制备多环氨基甲酰基吡啶酮化合物的方法
WO2022224120A1 (en) 2021-04-19 2022-10-27 Honour Lab Limited Polymorphic forms of bictegravir potassium
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023006087A1 (zh) * 2021-07-30 2023-02-02 南京明德新药研发有限公司 大环吡啶酮类化合物及其应用
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
PE20241341A1 (es) 2021-12-03 2024-07-03 Gilead Sciences Inc Compuestos terapeuticos para la infeccion por el virus vih
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en) 2022-06-21 2023-12-28 Mylan Laboratories Limited Polymorphic forms of bictegravir sodium
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
CN120379998A (zh) * 2022-09-20 2025-07-25 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
EP4529922A1 (en) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
US20250073172A1 (en) 2023-08-15 2025-03-06 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900736A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
HUP0104038A3 (en) 1998-11-09 2002-07-29 Black James Foundation Gastrin and cholecystokinin receptor ligand imidazole derivatives pharmaceutical compositions containing them and process for their preparation
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
HK1042701A1 (zh) 1998-12-25 2002-08-23 盐野义制药株式会社 具有hiv整合酶抑制活性的芳族雜環化合物
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
WO2002030426A1 (en) * 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
ES2383262T3 (es) 2001-08-10 2012-06-19 Shionogi & Co., Ltd. Agente antiviral
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1434577A1 (en) 2001-10-03 2004-07-07 Ucb, S.A. Pyrrolidinone derivatives
JP3927175B2 (ja) 2001-10-26 2007-06-06 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
MY136173A (en) 2002-11-20 2008-08-29 Japan Tobacco Inc 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1923063A3 (en) 2003-01-14 2009-04-08 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2005074513A2 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors
KR20070002006A (ko) 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (en) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
CA2563601A1 (en) * 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
EP1874117B8 (en) * 2005-04-28 2014-03-12 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
BRPI0620865A2 (pt) 2005-12-30 2011-11-29 Gilead Sciences Inc métodos para melhorar a farmacocinética de inibidores das integrases do hiv
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP1978960A4 (en) 2006-02-01 2009-12-02 Japan Tobacco Inc USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION
EA017861B9 (ru) 2006-03-06 2014-05-30 Джапан Тобакко Инк. Способ получения 4-оксохинолинового соединения
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2009000661A (es) 2006-07-19 2009-03-27 Univ Georgia Res Found Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion.
CN102766098B (zh) 2006-09-12 2016-03-30 吉里德科学公司 制备整合酶抑制剂的方法和中间体
JP2010506913A (ja) 2006-10-18 2010-03-04 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
US20110009411A1 (en) 2007-06-29 2011-01-13 Gilead Sciences ,Inc. Therapeutic compositions and the use thereof
WO2009006199A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EP2182801A4 (en) 2007-07-31 2011-04-13 Limerick Biopharma Inc COMPOSITIONS OF PYRONE ANALOGS AND METHODS
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010011813A1 (en) 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2449752T3 (es) * 2008-07-25 2014-03-21 Viiv Healthcare Company Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PL2320908T3 (pl) 2008-07-25 2014-06-30 Viiv Healthcare Co Proleki dolutegrawiru
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PT2376453T (pt) 2008-12-11 2020-01-14 Shionogi & Co Processos e intermediários para inibidores carbamoilpiridona da integrase de vih
MX383683B (es) * 2008-12-11 2025-03-11 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
JP2012512246A (ja) 2008-12-17 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
PT2393485E (pt) 2009-02-06 2015-10-23 Gilead Sciences Inc Comprimidos bicamada que compreendem elvitegravir, cobicistat, emtricitabina e tenofovir
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
ES2671550T3 (es) 2009-06-15 2018-06-07 Shionogi & Co., Ltd. Derivado de carbamoilpiridona policíclica sustituida
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
JP5765965B2 (ja) 2010-02-26 2015-08-19 日本たばこ産業株式会社 １，３，４，８−テトラヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
AU2011274322B2 (en) 2010-07-02 2015-08-13 Gilead Sciences, Inc. Naphth- 2 -ylacetic acid derivatives to treat AIDS
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
SMT202100268T1 (it) 2010-08-05 2021-07-12 Shionogi & Co Metodo per produrre composti aventi attività di inibizione di integrasi di hiv.
AU2011307087B2 (en) 2010-09-24 2016-11-10 Shionogi & Co., Ltd. Substituted polycyclic carbamoyl pyridone derivative prodrug
SG190333A1 (en) 2010-11-19 2013-06-28 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
KR20140027295A (ko) 2011-04-21 2014-03-06 길리애드 사이언시즈, 인코포레이티드 벤조티아졸 화합물 및 이들의 약학적 용도
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
HRP20171889T1 (hr) 2011-07-07 2018-01-12 Janssen Sciences Ireland Uc Formulacije kombinacije darunavira
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
AU2012321762A1 (en) 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
EP2877469A4 (en) 2012-07-25 2016-04-06 Merck Sharp & Dohme SUBSTITUTED NAPHTHYRIDEINDION DERIVATIVES AS HIV INTEGRASE INHIBITORS
MX337094B (es) 2012-08-03 2016-02-10 Gilead Sciences Inc Proceso e intermediarios para preparar inhibidores de integrasa.
CN104781254B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
US9795619B2 (en) 2012-12-14 2017-10-24 Glaxosmithkline Llc Pharmaceutical compositions
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US20160000721A1 (en) 2012-12-21 2016-01-07 Merck Sharp & Dohme Corp. Gastro-retentive formulations
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HUE028284T2 (en) 2012-12-21 2016-12-28 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
EP3008044B1 (en) 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (es) 2013-07-12 2018-07-21
PL3252058T3 (pl) * 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
ES2768658T3 (es) 2013-09-27 2020-06-23 Merck Sharp & Dohme Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del VIH
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
ES2770050T3 (es) 2014-01-21 2020-06-30 Laurus Labs Ltd Nuevo procedimiento para la preparación de dolutegravir y sus sales farmacéuticamente aceptables
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3466490B1 (en) 2015-04-02 2020-10-21 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN107847450A (zh) 2015-06-30 2018-03-27 吉利德科学公司 包含替诺福韦和恩曲他滨的药物制剂
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus

Also Published As

Publication number Publication date
CN116640140A (zh) 2023-08-25
MD4841B1 (ro) 2023-01-31
PE20151499A1 (es) 2015-10-29
CN104995198A (zh) 2015-10-21
AU2023286038A1 (en) 2024-01-25
HRP20191957T1 (hr) 2020-02-07
JP6028105B2 (ja) 2016-11-16
HUS1800035I1 (hu) 2018-09-28
LUC00083I2 (en) 2018-10-15
CY1117570T1 (el) 2017-04-26
JP6411409B2 (ja) 2018-10-24
PH12016500389A1 (en) 2018-10-01
HRP20160544T1 (hr) 2016-07-15
CA3012242C (en) 2021-11-02
PL3067358T3 (pl) 2020-02-28
UY35213A (es) 2014-06-30
KR20150096504A (ko) 2015-08-24
MX2022013596A (es) 2022-11-16
AU2020202914A1 (en) 2020-05-21
ZA201903516B (en) 2020-01-29
CY2018022I1 (el) 2019-07-10
NO2018026I2 (no) 2018-08-23
CN107674086B (zh) 2020-03-31
EP2822954A1 (en) 2015-01-14
US20190092787A1 (en) 2019-03-28
AU2013361401A1 (en) 2015-08-27
KR20190124814A (ko) 2019-11-05
BR122015029881B1 (pt) 2022-04-26
PT3067358T (pt) 2019-11-18
MD20150064A2 (ro) 2015-11-30
US20160176885A1 (en) 2016-06-23
ES2926068T3 (es) 2022-10-21
AP2015008510A0 (en) 2015-06-30
JP7301918B2 (ja) 2023-07-03
HUE028284T2 (en) 2016-12-28
RS54873B1 (sr) 2016-10-31
BR122015029881A2 (pt) 2016-03-22
TWI830624B (zh) 2024-01-21
TW202104229A (zh) 2021-02-01
IL247311A0 (en) 2016-09-29
BR112015014714A2 (pt) 2016-01-05
MX2015008009A (es) 2015-10-22
CR20170279A (es) 2017-10-19
EP4122935A1 (en) 2023-01-25
ZA201507997B (en) 2019-09-25
IL245780B (en) 2019-02-28
UA114351C2 (uk) 2017-05-25
MD4736C1 (ro) 2021-07-31
MX357940B (es) 2018-07-31
NO2018026I1 (no) 2018-08-23
MD4754C1 (ro) 2021-12-31
MX372534B (es) 2020-03-23
ME02400B (me) 2016-09-20
BR112015014714B1 (pt) 2018-12-26
HRP20220899T1 (hr) 2022-10-28
JP2019023204A (ja) 2019-02-14
EP3608325B1 (en) 2022-07-06
SI3608325T1 (sl) 2022-09-30
TW201918485A (zh) 2019-05-16
JP6571256B2 (ja) 2019-09-04
PH12015501445A1 (en) 2015-09-14
US10035809B2 (en) 2018-07-31
CA3012242A1 (en) 2014-06-26
US11548901B2 (en) 2023-01-10
KR20230061576A (ko) 2023-05-08
US20140221356A1 (en) 2014-08-07
KR101770048B1 (ko) 2017-08-21
JP2021193090A (ja) 2021-12-23
DK2822954T3 (en) 2016-05-30
TWI815245B (zh) 2023-09-11
WO2014100323A1 (en) 2014-06-26
DK3067358T3 (da) 2019-11-04
KR102040007B1 (ko) 2019-11-05
TW202400591A (zh) 2024-01-01
CA2893843A1 (en) 2014-06-26
AU2013361401C1 (en) 2018-08-09
JP2016508134A (ja) 2016-03-17
AU2016262722A1 (en) 2016-12-08
US9732092B2 (en) 2017-08-15
KR20220011789A (ko) 2022-01-28
US9216996B2 (en) 2015-12-22
IL239316A (en) 2016-09-29
KR20220080208A (ko) 2022-06-14
MY191741A (en) 2022-07-13
US10689399B2 (en) 2020-06-23
PH12016500389B1 (en) 2018-10-01
SI2822954T1 (sl) 2016-07-29
IL239316A0 (en) 2015-07-30
CA2893843C (en) 2018-09-04
AR094197A1 (es) 2015-07-15
AU2018232957B2 (en) 2020-01-30
JP6933690B2 (ja) 2021-09-08
AU2021221427A1 (en) 2021-09-16
KR102527797B1 (ko) 2023-05-03
ES2577283T3 (es) 2016-07-14
CL2017001191A1 (es) 2018-02-09
HK1205124A1 (en) 2015-12-11
ES2753548T3 (es) 2020-04-13
IL274988A (en) 2020-07-30
PT2822954E (pt) 2016-06-16
CL2015001756A1 (es) 2015-08-07
EP3608325A1 (en) 2020-02-12
PH12019501848A1 (en) 2020-03-02
LTPA2018511I1 (lt) 2018-10-10
HK1216643A1 (zh) 2016-11-25
KR20210049956A (ko) 2021-05-06
TWI752457B (zh) 2022-01-11
DK3608325T3 (da) 2022-08-22
PH12015501445B1 (en) 2015-09-14
EA037633B1 (ru) 2021-04-23
KR102351912B1 (ko) 2022-01-17
NZ709260A (en) 2016-07-29
AU2021221427B2 (en) 2023-10-12
JP2016179996A (ja) 2016-10-13
PL2822954T3 (pl) 2016-09-30
US20170260204A1 (en) 2017-09-14
EP3067358A1 (en) 2016-09-14
EP2822954B1 (en) 2016-03-09
JP2019218368A (ja) 2019-12-26
KR20170073733A (ko) 2017-06-28
US9663528B2 (en) 2017-05-30
CA3131094A1 (en) 2014-06-26
PL3608325T3 (pl) 2022-11-07
UA123572C2 (uk) 2021-04-28
AU2013361401B2 (en) 2017-01-05
CR20150380A (es) 2015-08-21
JP2023134483A (ja) 2023-09-27
CN111303152B (zh) 2023-04-11
KR102406288B1 (ko) 2022-06-13
AU2018232957A1 (en) 2018-10-11
IL245780A0 (en) 2016-08-02
EA201890236A1 (ru) 2018-10-31
MD4754B1 (ro) 2021-05-31
EP3067358B1 (en) 2019-08-07
EA201591027A1 (ru) 2016-05-31
US20170057976A1 (en) 2017-03-02
KR20200067930A (ko) 2020-06-12
CY2018022I2 (el) 2019-07-10
MY164352A (en) 2017-12-15
TW202212342A (zh) 2022-04-01
HK1250711A1 (zh) 2019-01-11
CN104995198B (zh) 2018-01-30
AU2016262722B2 (en) 2018-10-18
MD20200093A2 (ro) 2021-05-31
NL300947I2 (nl) 2018-09-26
PT3608325T (pt) 2022-10-17
KR102246963B1 (ko) 2021-04-30
CN111303152A (zh) 2020-06-19
CL2016000837A1 (es) 2016-10-21
NZ718708A (en) 2018-11-30
AU2020202914B2 (en) 2021-09-09
MX344879B (es) 2017-01-11
SMT201600157B (it) 2016-08-31
PE20170528A1 (es) 2017-05-28
TWI642669B (zh) 2018-12-01
HUE046559T2 (hu) 2020-03-30
LT3608325T (lt) 2022-09-12
US20210053988A1 (en) 2021-02-25
LT3067358T (lt) 2019-11-25
TW201441224A (zh) 2014-11-01
SI3067358T1 (sl) 2019-12-31
EA030003B1 (ru) 2018-06-29
CN107674086A (zh) 2018-02-09
HUE059688T2 (hu) 2022-12-28
MD4736B1 (ro) 2020-12-31
TWI693224B (zh) 2020-05-11
CY1122246T1 (el) 2020-11-25
LTC2822954I2 (lt) 2019-10-10
SG11201504857SA (en) 2015-07-30
KR102120875B1 (ko) 2020-06-09

Similar Documents

Publication Publication Date Title
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MX2013011944A (es) Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
MX356499B (es) Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas.
UA111982C2 (uk) Похідні бензотіазол-6-ілоцтової кислоти та їх застосування для лікування віл-інфекції